Previous research has implicated vascular endothelial growth factor (VEGF) in the
pathogenesis of diabetic retinopathy (DR). Although many studies reviewed the use of anti …

The treatment of ocular neovascular diseases is being revolutionized by intravitreal
therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for …

OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

Background Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age
population worldwide. Many observational and preclinical studies have implicated vascular …

Anti-vascular endothelial growth factor (anti-VEGF) crunch syndrome describes the
progression to tractional retinal detachment following intravitreal anti-VEGF therapy in an …

In the past years, the management of diabetic retinopathy (DR) relied primarily on a good
systemic control of diabetes mellitus, and as soon as the severity of the vascular lesions …

Twenty-five percent of diabetes-related vision loss stems from complications of proliferative
diabetic retinopathy (PDR). Panretinal photocoagulation has been the preferred treatment of …

Integrins are a class of transmembrane receptors that are involved in a wide range of
biological functions. Dysregulation of integrins has been implicated in many pathological …

Ocular angiogenesis and macular oedema are major causes of sight loss across the world.
Aberrant neovascularisation, which may arise secondary to numerous disease processes …

OBJECTIVE: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) injection
on the rate of early (≤ 4weeks) postvitrectomy hemorrhage in patients with proliferative …